EUS ROSE shows pancreatic cancer
An EUS rapid‑on‑site evaluation (ROSE) post shared images and a description consistent with pancreatic body adenocarcinoma — abundant cellularity, vacuolated cytoplasm, pleomorphic nuclei arranged in plaques and papillary groups on a mucinous background (x.com). The author classified the preparation as Papanicolaou C‑6 and WHO C‑7, which indicates a high degree of suspicion for malignancy on immediate assessment (x.com).
Doctors can spot pancreatic cancer by threading an ultrasound probe into the stomach and passing a thin needle into the pancreas to pull out cells for a same-procedure check. (pmc.ncbi.nlm.nih.gov) That test is called endoscopic ultrasound-guided fine-needle aspiration, and it is a standard way to sample a solid pancreatic mass. The “rapid on-site evaluation” step means a cytopathologist looks at the cells immediately to see whether the sample is adequate and whether it already looks malignant. (pathologyoutlines.com; pmc.ncbi.nlm.nih.gov) Pancreatic body adenocarcinoma refers to a cancer arising in the middle section of the pancreas, usually from the gland’s exocrine ducts. The American Cancer Society says most pancreatic cancers are exocrine cancers, and adenocarcinoma is the most common type. (cancer.org) Under the microscope, pathologists look for patterns that separate orderly tissue from cancerous tissue, much like comparing neat brickwork with a wall that has warped lines and broken edges. Features such as crowded cells, enlarged irregular nuclei, and mucin, a thick slippery substance, can point toward adenocarcinoma in the right clinical setting. (publications.iarc.who.int; pathologyoutlines.com) The older Papanicolaou Society reporting system uses six tiers, ending with category 6 for “positive or malignant.” The newer World Health Organization reporting system for pancreaticobiliary cytopathology links standardized categories to management and risk stratification across centers. (pathologyoutlines.com; publications.iarc.who.int) A same-day impression is not the whole workup. Final diagnosis usually folds in the permanent slides, cell block material, imaging, and sometimes surgical pathology or clinical follow-up before treatment is set. (pmc.ncbi.nlm.nih.gov; onlinelibrary.wiley.com) The reason clinicians use endoscopic ultrasound is simple: it can find very small pancreatic lesions and sample them in the same session. A 2019 review said experienced operators can detect focal lesions as small as 2 to 5 millimeters with endoscopic ultrasound. (pmc.ncbi.nlm.nih.gov) Rapid on-site evaluation can help confirm that the needle actually captured enough cells, but studies have found mixed results on whether it improves final accuracy. In one 2022 single-center study of 162 biopsies, diagnostic accuracy was 97.09% with rapid on-site evaluation and 96% without it, a difference the authors said was not statistically significant. (pmc.ncbi.nlm.nih.gov) That speed matters because pancreatic cancer is often found late and remains one of the deadliest major cancers. The National Cancer Institute says treatment depends on how far the disease has spread, and the Surveillance, Epidemiology, and End Results program lists a modeled 18.25% five-year relative survival for U.S. cases diagnosed in 2022. (cancer.gov; seer.cancer.gov) So when an on-site cytology read strongly favors malignancy during an endoscopic ultrasound biopsy, it is an early signal that the case is moving quickly from suspicion to confirmation. The next steps are usually staging, final pathology review, and treatment planning rather than another round of guesswork. (cancer.gov; pmc.ncbi.nlm.nih.gov)
